Magnim Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
About Magnim Biotech
Magnim Biotech Private Limited (MBPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 October 2020 (Four years and four months 7 days old ). Its registered office is in Rangareddy, Telangana, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Amarjit Giri, Vootukuru Swathi, Bharathi Maganti, and One other member serve as directors at the Company.
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24290TG2020PTC144878
- Company No.
144878
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Oct 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Magnim Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Radha Maganti  | Managing Director | 15-Oct-2020 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Amarjit Giri | Additional Director | 04-Aug-2023 | Current |
| Vootukuru Swathi | Additional Director | 04-Aug-2023 | Current |
| Bharathi Maganti | Director | 15-Oct-2020 | Current |
Financial Performance of Magnim Biotech.
Enhance accessibility to Magnim Biotech's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Magnim Biotech?
Unlock access to Magnim Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Magnim Biotech?
Magnim Biotech has a workforce of 0 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Magnim Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Magnim Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.